Skip to main navigation
Skip to search
Skip to main content
Bar-Ilan University Home
Help & FAQ
Home
Researchers
Organisations
Research output
Prizes
Student theses
Activities
Projects
Press/Media
Datasets
Equipment
Search by expertise, name or affiliation
Treatment of lupus nephritis: Facing the era of immunotherapy
A. A. Aran,
C. Putterman
Albert Einstein College of Medicine
Research output
:
Contribution to journal
›
Review article
›
peer-review
18
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Treatment of lupus nephritis: Facing the era of immunotherapy'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Abatacept
25%
Belimumab
25%
Biological Agents
25%
Cellular Immunology
25%
Central Pathway
25%
Conventional Treatment
25%
Corticosteroids
25%
Cyclophosphamide
25%
Disease Pathogenesis
25%
End-stage Renal Disease
25%
Epratuzumab
25%
Immunocompetence
25%
Immunomodulatory Effect
25%
Immunomodulatory Therapy
25%
Immunosuppression
25%
Inflammatory Response
25%
Infliximab
25%
Lupus Nephritis
100%
Molecular Immunology
25%
Novel Immunomodulators
25%
Patient Survival
25%
Renal Relapse
25%
Renal Survival
25%
Rituximab
25%
Sodium
25%
Tissue Damage
25%
Tocilizumab
25%
Traditional Treatment
25%
Treatment Protocol
25%
Medicine and Dentistry
Abatacept
25%
Abetimus
25%
Belimumab
25%
Biological Product
25%
Cellular Immunity
25%
Cyclophosphamide
25%
Disease
25%
End Stage Renal Disease
25%
Epratuzumab
25%
Immunocompetence
25%
Immunomodulating Agent
25%
Immunosuppressive Drug
25%
Immunosuppressive Treatment
25%
Immunotherapy
100%
Infliximab
25%
Lupus Nephritis
100%
Molecular Immunology
25%
Rituximab
25%
Serositis
25%
Side Effect
25%
Systemic Lupus Erythematosus
25%
Tissue Injury
25%
Tocilizumab
25%
Immunology and Microbiology
Abatacept
25%
Abetimus
25%
Adoptive Immunity
25%
Belimumab
25%
Biological Product
25%
Cyclophosphamide
25%
Epratuzumab
25%
Immunocompetence
25%
Immunomodulating Drugs
25%
Immunosuppression
25%
Immunosuppressive Drug
25%
Immunotherapy
100%
Inflammation Response
25%
Infliximab
25%
Lupus Erythematosus
100%
Molecular Immunology
25%
Nephritis
100%
Rituximab
25%
Systemic Lupus Erythematosus
25%
Tocilizumab
25%
Pharmacology, Toxicology and Pharmaceutical Science
Abatacept
25%
Abetimus
25%
Belimumab
25%
Biological Product
25%
Cyclophosphamide
25%
Disease
25%
End Stage Renal Disease
25%
Epratuzumab
25%
Immunomodulating Agent
25%
Immunosuppressive Agent
25%
Immunotherapy
100%
Inflammation
25%
Infliximab
25%
Lupus Erythematosus Nephritis
100%
Rituximab
25%
Side Effect
25%
Systemic Lupus Erythematosus
25%
Tissue Injury
25%
Tocilizumab
25%